Literature DB >> 7985084

Intermediate-risk group for differentiated carcinoma of thyroid.

A R Shaha1, T R Loree, J P Shah.   

Abstract

BACKGROUND: We have previously described prognostic factors in differentiated carcinoma of the thyroid gland relating to age, size and extrathyroid extension of the tumor, histologic grade, gender, and distant metastasis. These factors have identified patients in the low-risk group with excellent prognosis and the high-risk group with significant mortality. However, some patients fall within the intermediate-risk category where due deliberation in decision making is required for selection of appropriate treatment.
METHODS: A retrospective review of a consecutive series of 1038 previously untreated patients with differentiated carcinoma of thyroid treated during a period of 55 years was undertaken. Data gathered from review of the charts were subjected to univariate and multivariate analysis to assess prognostic factors. On the basis of the patient's age, presence of distant metastasis, and size, grade, and histologic characteristics of the tumor they could be classified into low-, intermediate-, and high-risk categories. Thus 403 (39%) patients were in the low-risk group, 232 (22%) patients in the high-risk category, and 403 (39%) patients in the intermediate-risk category.
RESULTS: With a median follow-up of 20 years, 99% survival was achieved in the low-risk group, whereas only 57% survived in the high-risk group. Interestingly, in the intermediate-risk category of 403 patients, the 20-year survival was only 85%. Our results clearly identify a distinct intermediate-risk category that includes low-risk patients with high-risk tumor or high-risk patients with low-risk tumor.
CONCLUSION: Patients in the intermediate-risk category should be considered for an aggressive treatment approach based on individual prognostic factors.

Entities:  

Mesh:

Year:  1994        PMID: 7985084

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  41 in total

1.  Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the Surveillance, Epidemiology, and End Results database.

Authors:  Ryan K Orosco; Timon Hussain; Kevin T Brumund; Deborah K Oh; David C Chang; Michael Bouvet
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

2.  Surgical decision making in the management of well-differentiated thyroid cancer.

Authors:  Natalya Chernichenko; Ashok R Shaha
Journal:  Indian J Surg Oncol       Date:  2012-05-01

Review 3.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

4.  Conservative management of well-differentiated thyroid cancer.

Authors:  Mazen Hassanain; Marvin Wexler
Journal:  Can J Surg       Date:  2010-04       Impact factor: 2.089

5.  Lateral Neck Lymph Node Characteristics Prognostic of Outcome in Patients with Clinically Evident N1b Papillary Thyroid Cancer.

Authors:  Laura Y Wang; Frank L Palmer; Iain J Nixon; R Michael Tuttle; Jatin P Shah; Snehal G Patel; Ashok R Shaha; Ian Ganly
Journal:  Ann Surg Oncol       Date:  2015-02-10       Impact factor: 5.344

6.  Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer.

Authors:  Daniel Mankarios; Peter Baade; Pip Youl; Robin H Mortimer; Adedayo A Onitilo; Anthony Russell; Suhail A R Doi
Journal:  Endocrine       Date:  2013-10-31       Impact factor: 3.633

7.  MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.

Authors:  Adriana Sondermann; Flavia Maziero Andreghetto; Ana Carolina Bernardini Moulatlet; Elivane da Silva Victor; Marilia Germanos de Castro; Fábio Daumas Nunes; Lenine Garcia Brandão; Patricia Severino
Journal:  Clin Exp Metastasis       Date:  2015-05-26       Impact factor: 5.150

8.  Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?

Authors:  Ian Ganly; Iain J Nixon; Laura Y Wang; Frank L Palmer; Jocelyn C Migliacci; Ahmad Aniss; Mark Sywak; Antoine E Eskander; Jeremy L Freeman; Michael J Campbell; Wen T Shen; Fernanda Vaisman; Denise Momesso; Rossana Corbo; Mario Vaisman; Ashok Shaha; R Michael Tuttle; Jatin P Shah; Snehal G Patel
Journal:  Thyroid       Date:  2015-08-12       Impact factor: 6.568

9.  Extent of surgery affects survival for papillary thyroid cancer.

Authors:  Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti; Cord Sturgeon
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

10.  The Updated AJCC/TNM Staging System for Papillary Thyroid Cancer (8th Edition): From the Perspective of Genomic Analysis.

Authors:  Kyubo Kim; Jin Hwan Kim; Il Seok Park; Young Soo Rho; Gee Hwan Kwon; Dong Jin Lee
Journal:  World J Surg       Date:  2018-11       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.